[Local application of mitoxantrone in inoperable, stenosing esophageal carcinoma. Preliminary report].
Two cases histories demonstrate the efficacy of mitoxantrone, a cytotoxic substance, after local application in inoperable, recurrent esophageal carcinoma. The drug is well tolerated. Local or systemic side-effects have not been observed so far. Up to 20 mg of mitoxantrone were administered at multiple sites into the tumor mass via the esophageal sclerosing system. So far the technique has been applied in 5 cases, and in each one we observed a transitory subjective and objective response.
D000287:Administration, Topical; D000368:Aged; D000880:Anthraquinones / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000188:drug therapy*; D004341:Drug Evaluation; D004938:Esophageal Neoplasms / Q000150:complications / Q000188:drug therapy*; D004940:Esophageal Stenosis / Q000188:drug therapy* / Q000209:etiology; D004945:Esophagoscopy; D006801:Humans; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone
D000880:Anthraquinones; D000970:Antineoplastic Agents; D008942:Mitoxantrone
Lokale Applikation von Mitoxantron beim inoperablen, stenosierenden Oesophaguskarzinom. Vorläufige Mitteilung.